Tag: BioMarin

A total of 21 posts are filed under BioMarin
BioMarin Collaborates with CureDuchenne to Transfers Natural History Database and Improve Knowledge, Improve Clinical Outcomes
 CureDuchenne announced today that BioMarin Pharmaceutical Inc. has transferred its Duchenne natural history database to CureDuchenne,… Continue Reading
Sarepta Planning to Dominate Duchennes in Rare Disease Race With BioMarin
By Damian Garde   Sarepta ($SRPT), jockeying with rival BioMarin ($BMRN) to commercialize a treatment for Duchenne muscular dystrophy, is… Continue Reading
CureDuchenne Cares Launches Website to Share Valuable Resources with the Duchenne Community
CureDuchenne, the national nonprofit dedicated to finding a cure for Duchenne muscular dystrophy, today unveiled the CureDuchenne Cares… Continue Reading
Mark Chapman Shares an Investor’s Guide for The Race To Cure Duchenne Muscular Dystrophy
Disclosure available at the source here. Summary Duchenne Muscular Dystrophy [DMD] is a deadly genetic disorder without any FDA approved… Continue Reading
Global Genes to Host Fourth Annual Tribute to Champions of Hope Gala and Patient Advocacy Summit
On September 26th, 2015, over 650 attendees from across the globe will gather at the Hyatt Regency Resort and Spa in Huntington Beach, CA,… Continue Reading
CureDuchenne Celebrates Submission of First-Ever New Drug Application for Duchenne Muscular Dystrophy
CureDuchenne Celebrates Submission of First-Ever New Drug Application for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping;… Continue Reading
Exclusivity: How The Government Keeps Orphan Drugs in Production
Why did the FDA grant BioMarin this permission, known in bureaucratic lingo as a “six-month pediatric exclusivity extension?” BioMarin… Continue Reading
be-a-guest-blogger

Follow us on Twitter